/CHNXF
CHNXF Stock - ChitogenX Inc.
Healthcare|BiotechnologyOTC
$0.00-85.43%
$0.01 (-85.43%) • Jan 12
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CHNXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.29
52W High$0.02
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-42,000 | $-59,000 | $-69,000 | $-89,000 | $-119,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-2,830,000 | $-4,892,000 | $-3,511,000 | $-2,760,000 | $-2,383,000 |
| Net Income | $-1,554,000 | $-6,230,000 | $-4,921,000 | $-3,772,000 | $-2,488,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.02 | $-0.13 | $-0.14 | $-0.13 | $-0.10 |
Company Overview
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CHNXFBeat Rate
33%
Last 15 quarters
Avg Surprise
-4.8%
EPS vs Estimate
Beats / Misses
5/5
5 met exactly
Latest EPS
$-0.01
Q4 2024
EPS Surprise History
Q2 23
-33.2%
$-0.03vs$-0.02
Q2 23
0.0%
$-0.02vs$-0.02
Q3 23
+50.0%
$-0.01vs$-0.02
Q1 24
0.0%
$-0.01vs$-0.01
Q1 24
+72.4%
$-0.00vs$-0.01
Q2 24
+32.8%
$-0.01vs$-0.01
Q3 24
+60.1%
$-0.00vs$-0.01
Q4 24
-39.5%
$-0.01vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Jan 12, 2026 | — | — | — | — |
Q4 2025 | Oct 16, 2025 | — | — | — | — |
Q4 2024 | Dec 22, 2024 | $-0.01 | $-0.01 | -39.5% | ✗ MISS |
Q3 2024 | Sep 27, 2024 | $-0.01 | $-0.00 | +60.1% | ✓ BEAT |
Q2 2024 | May 27, 2024 | $-0.01 | $-0.01 | +32.8% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | $-0.01 | $-0.00 | +72.4% | ✓ BEAT |
Q1 2024 | Jan 2, 2024 | $-0.01 | $-0.01 | 0.0% | = MET |
Q3 2023 | Sep 29, 2023 | $-0.02 | $-0.01 | +50.0% | ✓ BEAT |
Q2 2023 | Jun 29, 2023 | $-0.02 | $-0.02 | 0.0% | = MET |
Q2 2023 | May 31, 2023 | $-0.02 | $-0.03 | -33.2% | ✗ MISS |
Q4 2022 | Dec 28, 2022 | $-0.02 | $-0.03 | -33.3% | ✗ MISS |
Q3 2022 | Sep 28, 2022 | $-0.02 | $-0.02 | 0.0% | = MET |
Q2 2022 | Jun 23, 2022 | — | $-0.02 | — | — |
Q2 2022 | May 19, 2022 | $-0.02 | $-0.02 | +18.6% | ✓ BEAT |
Q4 2021 | Dec 21, 2021 | $-0.03 | $-0.06 | -100.0% | ✗ MISS |
Q3 2021 | Sep 30, 2021 | $-0.03 | $-0.03 | 0.0% | = MET |
Q2 2021 | Jun 29, 2021 | — | $-0.03 | — | — |
Q2 2021 | May 31, 2021 | $-0.02 | $-0.04 | -100.0% | ✗ MISS |
Q4 2020 | Dec 17, 2020 | $-0.03 | $-0.03 | 0.0% | = MET |
Q3 2020 | Sep 24, 2020 | — | $-0.02 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CHNXF
What is CHNXF's current stock price?
ChitogenX Inc. (CHNXF) is currently trading at $0.00 per share. The stock has moved -85.43% today.
What is the analyst price target for CHNXF?
No analyst price targets are currently available for this stock.
What sector is ChitogenX Inc. in?
ChitogenX Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is CHNXF's market cap?
ChitogenX Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CHNXF pay dividends?
No, ChitogenX Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBSYI
BioSyntech, Inc.
$0.00
Mkt Cap: $0.0B
IPIX
Innovation Pharmaceuticals Inc.
$0.00
Mkt Cap: $0.0B
LFCOF
Lift & Co. Corp.
$0.00
Mkt Cap: $0.0B
MDIN
MedGen, Inc.
$0.00
Mkt Cap: $0.0B
NBIO
Nascent Biotech, Inc.
$0.00
Mkt Cap: $0.0B
RASP
Actavia Life Sciences, Inc.
$0.00
Mkt Cap: $0.0B
RGRX
RegeneRx Biopharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
TEVNF
Tevano Systems Holdings Inc.
$0.00
Mkt Cap: $0.0B
VIVXF
Avivagen Inc.
$0.00
Mkt Cap: $0.0B
WSNAF
Wesana Health Holdings Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to CHNXF for comparison